Merck close to $6B acquisition of Terns Pharma to boost cancer portfolio: FT (MRK:NYSE)

Merck nears a $6B all-cash buyout of Terns to bolster its drug pipeline before Keytruda’s 2028 patent expiry.

You will be redirected in 10 seconds.

liveinternet liveinternet